About Reprieve Cardiovascular
Reprieve Cardiovascular is a private company based in Milford, Massachusetts, incorporated in 2020 in Delaware. It has reported $82,424,998 raised in five offerings on Form D since August 2020. Its chief executive is Mark Pacyna.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| May 28, 2025 | Jun 5, 2025 | $30,852,111of $35.8M target | 12 | $2.5M | EquityRule 506(b) | Form D ↗ |
| Sep 26, 2024 | Oct 2, 2024amended Jan 27, 2025 | $9,522,886of $10.5M target | 8 | $1.1M | Debt, Securities on exerciseRule 506(b) | Form D/A ↗1 earlier filing |
| Nov 9, 2023 | Nov 20, 2023 | $12,050,001fully sold | 7 | $1.7M | EquityRule 506(b) | Form D ↗ |
| Apr 29, 2022 | Jun 8, 2022 | $15,000,000fully sold | 6 | $2.5M | EquityRule 506(b) | Form D ↗ |
| Jul 22, 2020 | Aug 4, 2020 | $15,000,000fully sold | 6 | $2.5M | EquityRule 506(b) | Form D ↗ |
| Total, five offerings | $82,424,998 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Reprieve Cardiovascular's Form D filed Jun 5, 2025.
JG
Jan Garfinkle
Director
TF
Tony Fields
Executive officer
EB
Ethan Benovitz
Director
JE
HI
Hanson Gifford III
Director
AB
Adam Bartnik
Executive officer
DN
David Neustaedter
Director
Earlier filings also listed Gregory Mann (executive officer, last listed Nov 2023), Jim Dillon (executive officer and director, last listed Jun 2022) and Andrew ElBardissi (director, last listed Jun 2022).